Roche CEO Thomas Schinecker told the “Financial Times” that the company’s first anti-obesity drugs would come onto the market “much faster than expected” – possibly by 2028. This booming market is currently dominated by the American company Eli Lilly and the Danish company Novo Nordisk.
In mid-July, Roche once again published positive study data on a potential weight loss drug. This involved the candidate CT-996, which is taken once a day to treat type 2 diabetes and obesity. The drug comes from the portfolio of the American company Carmot, which Roche acquired in December for around $3 billion.
Like several anti-obesity drugs in development, CT-996 belongs to the new class of lipid-lowering drugs, the GLP-1 drugs. It achieved significant results in two sub-studies of an ongoing multi-part Phase I clinical trial. Only shortly before this, Roche had published data on its other obesity candidate CT-388, which had been positively received by analysts and investors.
Schinecker told the Financial Times that Roche could have “around seven” drugs from the Carmot acquisition, some of which are in even earlier stages of development. Roche shares have also recently benefited from the trial data.
The multi-billion dollar market for so-called GLP-1 drugs is becoming increasingly competitive. Many pharmaceutical companies, including industry giants Pfizer and Boehringer Ingelheim, are working on competing products to those of Eli Lilly and Novo Nordisk.
Adapted from German by DeepL/ac
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Is reforming the Swiss pension system still possible, and if so, how?
Solutions still need to be found to meet the challenge of an ageing population and to improve the pensions of low-paid workers, the majority of whom are women.
This content was published on
The Swiss federal technology institute ETH Zurich is the best university in continental Europe, according to the Times Higher Education ranking.
NGO accuses tobacco industry and Switzerland of human rights violations
This content was published on
The anti-smoking NGO OxySuisse has accused tobacco companies of violating human rights and the Swiss authorities of being complacent.
Swiss national injured in attack on Beirut building
This content was published on
A Swiss national was slightly injured following an attack on a building in Beirut, Swiss media agency Keystone-ATS learned on Tuesday.
Kate Winslet receives Golden Icon award at Zurich Film Festival
This content was published on
British actress Kate Winslet took a dip in Lake Zurich before receiving the Golden Icon Award for lifetime achievement at the Zurich Film Festival.
Swiss President remembers victims of October 7 attack
This content was published on
One year after the attack on Israel by Hamas, Swiss President Viola Amherd remembered the victims and called for the release of all hostages.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.